基线18F-FDG PET/CT骨髓滞留指数与骨髓-肝脏比值在弥漫性大B细胞淋巴瘤中的预后价值
本前瞻性研究纳入135例新诊断弥漫性大B细胞淋巴瘤患者,均接受双时相18F-FDG PET/CT及R-CHOP方案化疗。骨髓滞留指数(RI-bm)和骨髓-肝脏比值(BLR)较高者2年无复发生存率和总生存率均显著低于较低者,两者均为独立预后因素。
要点
- 基线双时相PET/CT测量的骨髓RI-bm和BLR较高与DLBCL患者较差的RFS和OS显著相关。
- 高RI-bm组2年RFS为20%,低RI-bm组为65.1%(p < 0.001)。
- 高BLR组2年RFS为30.2%,低BLR组为69.6%(p < 0.001)。
核心结论
- 基线RI-bm和BLR是DLBCL患者强有力的独立预后因素。
研究设计与样本
- 前瞻性研究,纳入135例新诊断DLBCL患者,均接受双时相18F-FDG PET/CT并接受R-CHOP方案化疗,于治疗结束时评估疗效。
关键影像表现/征象
- 计算肿瘤和骨髓的早期及延迟SUVmax、SUVmax增量(SUVinc)、滞留指数(RI)和骨髓-肝脏比值(BLR)。
- 高RI-bm组2年RFS为20%,低RI-bm组为65.1%(p < 0.001)。
- 高BLR组2年RFS为30.2%,低BLR组为69.6%(p < 0.001)。
- 高RI-bm组2年OS为60%,低RI-bm组为76.3%(p = 0.023)。
- 高BLR组2年OS为57.3%,低BLR组为78.6%(p = 0.035)。
诊断标准与关键数值
- 单因素分析显示RI-bm对RFS的HR = 4.02(p < 0.001),BLR对RFS的HR = 3.23(p < 0.001)。
- 单因素分析显示RI-bm对OS的HR = 2.83(p = 0.030),BLR对OS的HR = 2.38(p = 0.041)。
临床应用与阅片要点
- RI-bm和BLR可能作为无创的PET/CT参数用于预测新诊断DLBCL患者治疗前风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine prognostic value of bone marrow retention index (RI-bm) and bone marrow-to-liver ratio (BLR) measured on baseline dual-phase 18F-FDG PET/CT in a series of newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) treated homogeneously with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy.
PATIENTS AND METHODS: This prospective study enrolled 135 patients with newly diagnosed DLBCL. All patients underwent dual-phase 18F-FDG PET/CT. The following PET parameters were calculated for both tumor and bone marrow: maximum standardized uptake value (SUVmax) at both time points (SUVmax early and SUVmax delayed), SUVmax increment (SUVinc), RI, and BLR. Patients were treated with R-CHOP regimen and response at end of treatment was assessed.
RESULTS: The final analysis included 98 patients with complete remission. At a median follow-up of 22 months, 57 patients showed no relapse, 74 survived, and 24 died. The 2-year relapse-free survival (RFS) values for patients with higher and lower RI-bm were 20% and 65.1%, respectively (p < 0.001), and for patients with higher and lower BLR were 30.2% and 69.6%, respectively (p < 0.001). The 2-year overall survival (OS) values for patients with higher and lower RI-bm were 60% and 76.3%, respectively (p = 0.023), and for patients with higher and lower BLR were 57.3% and 78.6%, respectively (p = 0.035). Univariate analysis revealed that RI-bm and BLR were independent significant prognostic factors for both RFS and OS (hazard ratio [HR] = 4.02, p < 0.001, and HR = 3.23, p < 0.001, respectively) and (HR = 2.83, p = 0.030 and HR = 2.38, p = 0.041, respectively).
CONCLUSION: Baseline RI-bm and BLR were strong independent prognostic factors in DLBCL patients.
CLINICAL RELEVANCE STATEMENT: Bone marrow retention index (RI-bm) and bone marrow-to-liver ratio (BLR) could represent suitable and noninvasive positron emission tomography/computed tomography (PET/CT) parameters for predicting pretreatment risk in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy.
KEY POINTS: • Bone marrow retention index (RI-bm) and bone marrow-to-liver ratio (BLR) are powerful prognostic variables in diffuse large B-cell lymphoma (DLBCL) patients. • High BLR and RI-bm are significantly associated with poor overall survival (OS) and relapse-free survival (RFS). • RI-bm and BLR represent suitable and noninvasive risk indicators in DLBCL patients.
引用
- El-Azony A, Basha MAA, Almalki YE, et al. The prognostic value of bone marrow retention index and bone marrow-to-liver ratio of baseline 18F-FDG PET/CT in diffuse large B-cell lymphoma. Eur Radiol. 2023. PMID: 37812294. doi:10.1007/s00330-023-10150-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。